31

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Art Unit: 1627
PAIGE, et al.	Examiner: WESSENDORF, T.
Serial No.: 09/429,331	Washington, D.C.
Filed: October 28, 1999	December 31, 2003
For: METHOD OF PREDICTING THE ABILITY OF COMPOUNDS TO...)	Docket No.: PAIGE=1D

INFORMATION DISCLOSURE STATEMENT [IDS]

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop DD
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

S i r :

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:

[ ] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application. See 37 CFR 1.97(b)(1) and (3).

[X] B. before the mailing date of a first office action on the merits. See 37 CFR 1.97(b).

[ ] C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below). See 37 CFR 1.97(c)(2).

[ ] i. Counsel certifies that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign

patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[ ] ii. Credit Card Payment Form, PTO-2038, authorizing payment for the fee set forth in 1.17(p), presently believed to be $180, is attached.

[ ] D. after (A), (B) and (C) above, but before payment of the issue fee. Applicant petitions under 37 C.F.R. 1.97(d) for consideration of this IDS. A Credit Card Payment Form, PTO-2038, authorizing payment for the fee set forth in 1.17(p)(1), presently believed to be $180 is attached. Counsel certifies that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

[ ] E. As a submission in accordance with the transitional procedure for limited examination after final rejection pursuant to 37 CFR §1.129(a). Pursuant to MPEP §706.07(g), page 700-66, col. 2 (August 2001), this IDS is treated as if filed with a period set forth in 37 CFR §1.97(b) and considered without the petition and petition fee required by 1.97(d).

[ ] F. As a submission with or after a request for continued examination under CFR §1.114, and before the mailing of a first office action on the RCE. See 37 CFR §1.97(b)(4).

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office,

either incorporated into this IDS or as an attachment hereto. A copy of each document is attached, except as explained below.

[ ] While an IDS filed under §1.97 must contain a "list of all patents, publications or other information submitted for consideration by the Office", see §1.98(a) (1), the only requirement for the list is that it provide the information set forth in §1.98(b). There is no requirement that a form PTO-1449 be used (MPEP §609 merely says that use of this form is "encouraged"). Counsel has used a list provided to him by Applicants, and not transferred the information to a PTO-1449, to avoid the risk of any inadvertent error in transferring the information.

[ ] A. Documents _____ are deemed substantially cumulative to documents _____, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.

[ ] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

[insert serial number/filing date]

Applicants identify these documents by attaching hereto copies of the form PTO-892s and PTO-1449s from the files of the prior applications or a fresh PTO-1449 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application. If copies of any of these documents cannot be found in the files of the prior applications, the Examiner is requested to so notify counsel before taking action in this case, so replacement copies can be submitted. While an IDS filed under §1.97 must contain a "list of all patents, publications or other information submitted for consideration by the Office", see §1.98(a) (1), the only requirement for the list is that it provide the information set forth in §1.98(b). There is no requirement that a form PTO-1449 be used (MPEP §609 merely says that use of this form is "encouraged") and no prohibition on submitting a copy of a form

PTO-1449 or form PTO-892 from a prior case. Indeed, the re-use of such forms is desirable as it avoids error in transferring the information, and evidences that the reference was considered in a prior application. A previously accepted PTO-1449, or an examiner-prepared PTO-892, necessarily complies with §1.98(b).

[ ] C. Document(s) _____ is (are) U.S. patent(s) and/or published application(s). As this is a U.S. application filed after June 30, 2003, or an entry into national stage under 35 USC §371 after June 30, 2003, the requirement to file copies of such U.S. patents or published applications has been waived. (Office of Patent Legal Administration - Pre O.G. Notice of July 11, 2003).

[ ] 3. Documents _____ are not in the English language. In accordance with 1.98(a)(3), Applicants state:

[ ] documents _____ already contain an English language abstract, summary or claim set.

[ ] a publicly available abstract is attached to each of documents ___, and the source of each abstract is indicated thereon.

[ ] documents ___ are patents or published patent applications for which counterpart English language patents or patent applications exist, and are enclosed, as follows:

Foreign Lang. Doc.#	English Lang. Doc.#
[insert]	[insert]

[ ] applicants have prepared an English translation of at least the pertinent portions of documents _____, and copies are attached.

[ ] A concise explanation of the relevance of documents _____ is found in the attached search report from the _____ Patent Office (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

[ ] A concise explanation of the relevance of documents _____ is set forth as follows:

[Insert concise explanation of relevance]

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. If the month of publication of a nonpatent reference is not stated, it is because it is not apparent from review of the reference. If requested to do so by the Examiner, Applicants will attempt to locate and write to the publisher.

If the publication date of a cited document is set forth only as a publication year, and that year is prior to the year of filing or, if priority is claimed, year of priority of this application, then the particular month of publication is not in issue. Likewise if that publication year is after the year of filing of this application, the month of publication is not in issue.

If the date of publication of a nonpatent reference is stated, then, except as explained below, it is the nominal date stated in the reference, or in a larger document (journal or book) from which the reference was extracted. Applicants reserve the right to challenge this date by contacting the publisher to determine the actual shipment date, or by contacting recipients to determine the receipt dates.

6. Other information being provided for the examiner's consideration follows:

[insert other information]

7. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

8. The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection

with this paper or credit any overpayment to Deposit Account No. 02-4035.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: _____
Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202)628-5197
Facsimile: (202)737-3528
IPC:lms
G:\ipc\n-q\Nova\Paige1D\ptoids.wpd

FORM PTO-1449
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF DOCUMENTS CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO: PAIGE=1D | SERIAL NO: 09/429,331

APPLICANT: PAIGE, et al.

FILING DATE: October 28, 1999 | GROUP: 1627

U.S. PATENT DOCUMENTS (include at least patentee, patent number and issue date)

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	PATENTEE	CLASS	SUB-CLASS	FILING DATE IF APPROP.
	AA	4 6 6 4 9 8 9	12MAY1987	JOHNSON			
	AB	5 0 7 1 7 7 3	10DEC1991	EVANS, et al			
	AC	5 1 9 8 3 4 6	30MAR1993	LADNER, et al.			
	AD	5 2 1 7 8 6 7	08JUN1993	EVANS, et al.			
	AE	5 2 2 3 4 0 9	29JUN1993	LADNER, et al.			
	AF	5 2 9 8 4 2 9	29MAR1994	EVANS, et al.			
	AG	5 4 4 5 9 4 1	29AUG1995	YANG			
	AH	5 5 0 6 3 3 7	09APR1996	SUMMERTON, et al.			
	AI	5 5 4 5 5 6 8	13AUG1996	ELLMAN			
	AJ	5 5 8 7 2 9 3	24DEC1996	KAUVAR, et al.			
	AK	5 5 9 5 8 7 7	21JAN1997	GOLD, et al.			
	AL	5 7 0 7 8 0 3	13JAN1998	LAMB, et al.			
	AM	5 7 2 3 2 9 1	03MAR1998	KUSHNER, et al.			
	AN	5 7 8 9 1 8 4	04AUG1998	FOWLKES, et al.			
	AO	5 8 1 4 5 1 7	29SEP1998	SEIDEL, et al.			
	AP	5 8 8 2 9 4 4	16MAR1999	SADEE			

FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country)

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES/NO
	AQ	9 8 3 4 1 2 0	06AUG1998	WIPO			YES
	AR	9 8 3 4 9 4 8	12AUG1998	WIPO			YES
	AS	9 8 4 4 3 5 0	08OCT1998	WIPO			YES
	AT	0 0 2 2 1 1 2	20APR2000	WIPO			YES
	AU	0 0 2 3 4 6 5	27APR2000	WIPO			YES

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO: PAIGE=1D	SERIAL NO:09/429,331
	APPLICANT: PAIGE, et al.	
	FILING DATE: October 28, 1999	GROUP: 1627

OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)

	AV	ALFANO, et al., Time-Resolved and Nonlinear Optical Imaging for Medical Applications, ANN. N.Y. ACAD. SCI., vol. 838, pgs. 14-27, 1998.
	AW	ALLEN, et al., Finding prospective partners in the library: the two-hybrid system and phage display find a match, TIBS, vol. 20, pgs. 511-516, (1995).
	AX	ANZICK, et al., AlB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer, SCIENCE, vol. 277, pgs. 965-968, August 15, 1997.
	AY	ARKINSTALL, et al., Mapping regions of $G_{\alpha q}$ interacting with PLCβ1 using multiple overlapping synthetic peptides, FEBS LETTERS, vol. 364, pgs. 45-50, 1995.
	AZ	BEEKMAN, et al., Transcriptional Activation by the Estrogen Receptor Requires a Conformational change in the ligand Binding Domain, MOLECULAR ENDOCRINOLOGY, vol. 7, no. 10, pgs. 1266-1274, 1993.
	BA	BENDIXEN, et al., A yeast mating-selection scheme for detection of protein - protein interactions, NUCLEIC ACIDS RESEARCH, vol. 22, no. 9, pgs. 1778-1779, 1994.
	BB	BRENT, et al., Understanding Gene and Allele Function with Two-Hybrid Methods, ANNU. REV. GENET., vol. 31, pgs. 663-704, 1997.
	BC	BROACH, et al., High-throughput screening for drug discovery, NATURE, vol. 384, pgs. 14-16, November 7, 1996.
	BD	BRZOZOWSKI, et al., Molecular basis of agonism and antagonism in the oestrogen receptor, NATURE, vol. 389, pgs. 753-758, October 16, 1997.
	BE	BUNIN, et al., Synthesis and Evaluation of 1,4-Benzodiazepine Libraries, METHODS IN ENZYMOLOGY, vol. 267, pgs. 448-465, 1996.
	BF	BUNIN, et al., The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library, PROC. NATL. ACAD. SCI. USA, vol. 91, pgs. 4708-4712, May 1994.
	BG	CHAHDI, et al., Drugs interacting with G protein α subunits: selectivity and perspectives, FUNDAM CLIN PHARMACOL., vol. 12, pgs. 121-132, 1998.
	BH	CHAMBRAUD, et al., Several Regions of Human Estrogen Receptor are Involved in the Formation of Receptor-Heat Shock Protein 90 Complexes, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 33, pgs. 20686-20691, November 25, 1990.
	BI	CHANG, et al., Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β, MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 12, pgs. 8226-8239, December 1999.
	BJ	CHEN, et al., Analogous Organic Synthesis of Small-Compound Libraries: Validationo f Combinatorial Chemistry in Small-Molecule Synthesis, J. AM. CHEM. SOC., vol. 116, pgs. 2661-2662, 1994.
	BK	COHEN, et al., An artificial cell-cycle inhibitor isolated from a combinatorial library, PROC. NATL. ACAD. SCI. USA, vol. 95, pgs. 14272-14277, November 1998.
	BL	COLAS, et al., Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2, NATURE, vol. 380, pgs. 548-550, April 11, 1996.
	BM	CONKLIN, et al., Substitution of three amino acids switches receptor specificity of $G_q\alpha$ to that of $G_i\alpha$, NATURE, vol. 363, pgs. 274-276, May 20, 1993.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO: PAIGE=1D	SERIAL NO: 09/429,331
	APPLICANT: PAIGE, et al.	
	FILING DATE: October 18, 1999	GROUP: 1627

OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)

	BN	CUMMINS, et al., Molecular Diversity in Chemical Databases: Comparison of Medicinal Chemistry Knowledge Bases and Databases of Commercially Available Compounds, J. CHEM. INF. COMPUT. SCI., vol. 36, pgs. 750-763, 1996.
	BO	DEWITT, et al., "Diversomers": An approach to nonpeptide, nonoligomeric chemical diversity, PROC. NATL. ACAD. SCI. USA, vol. 90, pgs. 6909-6913, August 1993.
	BP	DMITROVA, et al., A new LexA-based genetic system for monitoring and analyzing protein heterodimerization in *Escherichia coli*, MOL. GEN GENET, vol. 257, pgs. 205-212, 1998.
	BQ	ESTOJAK, et al., Correlation of Two-Hybrid Affinity Data with In Vitro Measurements, MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 10, pgs. 5820-5829, October 1995.
	BR	FONG, et al., Selective Activation of a Chimeric G_{i1}/G_s G Protein α Subunit by the Human IP Prostanoid Receptor: Analysis Using Agonist Stimulation of High Affinity GTPase Activity and [35S]Guanosine-5'-O-(3-thio)triphosphate Binding, MOLECULAR PHARMACOLOGY, vol. 54, pgs. 249-257, 1998.
	BS	FROMONT-RACINE, et al., Toward a Functional analysis of the yeast genome through exhaustive two-hybrid screens, NATURE GENETICS, vol. 16, pgs. 277-281, July 16, 1997.
	BT	FULLER, et al., Development of a Yeast Trihybrid Screen Using Stable Yeast Strains and Regulated Protein Expression, BIOTECHNIQUES, vol. 25, no. 1, pgs. 85-92, July 1998.
	BU	GALLO, et al., Antagonistic and Agonistic Effects of Tamoxifen: Significance in Human Cancer, SEMINARS IN ONCOLOGY, vol. 24, no. 1, suppl. 1, pgs. SI-71 - SI-80, February 1997. Missing page SI-79.
	BV	GONZÀLEZ, et al., Intracellular detection assays for high-throughput screening, CURRENT OPINION IN BIOTECHNOLOGY, vol. 9, pgs. 624-631, 1998.
	BW	GUDERMANN, et al., Functional and Structural Complexity of Signal Transduction Via G-Protein-Coupled Receptors, ANNU. REV. NEUROSCI., vol. 20, pgs. 399-427, 1997.
	BX	GUDERMANN, et al., Specificity and Complexity of Receptor-G-Protein Interaction, ADVANCES IN SECOND MESSENGER AND PHOSPHOPROTEIN RESEARCH, vol. 31, pgs. 253-262, 1997.
	BY	GUDERMANN, et al., Diversity and Selectivity of Receptor-G Protein Interaction, ANNU. REV. PHARMACOL. TOXICOL. vol. 36, pgs. 420-459, 1996.
	BZ	HEERY, et al., A signature motif in transcriptional co-activators mediates binding to nuclear receptors, NATURE, vol. 387, pgs. 733-736, June 12, 1997.
	CA	HIMMLER, et al., Functional Testing of Human Dopamine D_1 and D_5 Receptors Expressed in Stable cAMP-Responsive Luciferase Reporter Cell Lines, JOURNAL OF RECEPTOR RESEARCH, vol. 13(1-4), pgs. 79-94, 1993.
	CB	HOWELL, et al., Antiestrogens: Future Prospects, ONCOLOGY, vol. 11, no. 2, supplement no. 1, pgs. 59-64, February 1997.
	CC	KALKBRENNER, et al., Specificity of interaction between receptor and G protein: use of antisense techniques to relate G-protein subunits to function, BIOCHIMICA ET BIOPHYSICA ACTA., vol. 1314, pgs. 125-139, 1996.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO: PAIGE=1D	SERIAL NO: 09/429,331
LIST DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT: PAIGE, et al.	
	FILING DATE: October 28, 1999	GROUP: 1627

OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)

	CD	KARIMOVA, et al., A bacterial two-hybrid system based on a reconstituted signal transduction pathway, PROC. NATL. ACAD. SCI. USA, vol. 95, pgs. 5752-5756, May 1998.
	CE	KATZENELLENBOGEN, et al., Antiestrogens: Mechanisms of action and resistance in breast cancer, BREAST CANCER RESEARCH AND TREATMENT, vol. 44, pgs. 23-38, 1997.
	CF	KAUVAR, et al., Predicting ligand binding to proteins by affinity fingerprinting, CHEMISTRY & BIOLOGY, vol. 2, pgs. 107-118, February 1995.
	CG	KLEBE, et al., On the Prediction of Binding Properties of Drug Molecules by Comparative Molecular Field Analysis, J. MED. CHEM., vol. 36, pgs. 70-80, 1993.
	CH	KLUG, et al., All you wanted to know about SELEX, MOLECULAR BIOLOGY REPORTS, vol. 20, pgs. 97-107, 1994.
	CI	KOLONIN, et al., Targeting cyclin-dependent kinases in *Drosophila* with peptide aptamers, PROC. NATL. ACAD. SCI. USA, vol. 95, pgs. 14266-14271, November 1998.
	CJ	KRAUS, et al., Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor, PROC. NATL. ACAD. SCI. USA, vol. 92, pgs. 12314-12318, December 1995.
	CK	KUIPER, et al., The novel estrogen receptor-β subtype: potential role in the cell- and promoter-specific actions of estrogen and anti-estrogens, FEBS LETTERS, vol. 410, pgs. 87-90, 1997.
	CL	LANDEL, et al., The Interaction of Human Estrogen Receptor with DNA is Modulated by Receptor-Associated Proteins, MOLECULAR ENDOCRINOLOGY, vol. 8, no. 10, pgs. 1407-1419, 1994.
	CM	LAVINSKY, et al., Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes, PROC. NATL. ACAD. SCI. USA, vol. 95, pgs. 2920-2925, March 1998.
	CN	LECRENIER, et al., Two-hybrid systematic screening of the yeast proteome, BIOESSAYS, vol. 20, pgs. 1-5, 1998.
	CO	LUNDBLAD, et al., Fluorescence Polarization Analysis of Protein-DNA and Protein-Protein Interactions, MOLECULAR ENDOCRINOLOGY, vol. 10, no. 6, pgs. 607-612, 1996.
	CP	MACGREGOR, et al., Basic Guide to the Mechanisms of Antiestrogen Action, PHARMACOLOGICAL REVIEWS, vol. 50, no. 2, pgs. 151-158, 1998. Missing pages after 158.
	CQ	MARTIN, et al., Potent Peptide Analogues of a G protein Receptor-Binding Region Obtained with a Combinatorial Library, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 1, pgs. 361-366, January 5, 1996.
	CR	MATTER, Hans, Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors, J. MED. CHEM., vol. 40, pgs. 1219-1229, 1997.
	CS	MCDONNELL, et al., Development of Tissue-Selective Estrogen Receptor Modulators, ERNST SCHERING RESEARCH FOUNDATION, Workshop 16, ORGAN-SELECTIVE ACTIONS OF STEROID HORMONES, pgs. 1-28.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO: PAIGE=1D	SERIAL NO: 09/429,331
LIST DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT: PAIGE, et al.	
	FILING DATE: October 28, 1999	GROUP: 1627

OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)

	CT	MCDONNELL, D.P., Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators, BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 26, pgs. 54-60, 1998.
	CU	MCDONNELL, et al, Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors, CANCER BIOLOGY, vol. 5, pgs. 327-336, 1994.
	CV	MCDONNELL, et al., In Situ Distinction between Steroid Receptor Binding and Transactivation at a Target Gene, MOLECULAR AND CELLULAR BIOLOGY, vol. 11, no. 9, pgs. 4350-4355, September 1991.
	CW	MCINERNEY, et al., Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation, GENES & DEVELOPMENT, vol. 12, pgs. 3357-3368, 1998.
	CX	MILLAR, et al., Time-resolved fluorescence spectroscopy, CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 6, pgs. 637-642, 1996.
	CY	MILLIGAN, et al., Chimaeric Gα proteins: their potential use in drug discovery, TRENDS PHARMACOL. SCI, vol. 20, pgs. 118-24, 1999.
	CZ	MITRA, et al., Fluorescence resonance energy transfer between blue-emitting and red-shifted excitation derivatives of the green fluorescent protein, GENE, vol. 173, pgs. 13-16, 1996.
	DA	MOCHIZUKI, et al., Identification and cDNA cloning of a novel human mosaic protein, LGN, based on interaction with $G_{\alpha i2}$, GENE vol. 181, pgs. 39-43, 1996.
	DB	MOHLER, et al., Gene expression and cell fusion analyzed by *lacZ* complementation in mammalian cells, PROC. NATL. ACAD. SCI. USA, vol. 93, pgs. 12423-12427, October 1996.
	DC	MONTANO, et al., The Carboxy-Terminal F Domain of the Human Estrogen Receptor: Role in the Transcriptional Activity of the Receptor and the Effectiveness of Antiestrogens as Estrogen Antagonists, MOLECULAR ENDOCRINOLOGY, vol. 9, no. 7, pgs. 814-825, 1995.
	DD	NEFZI, et al., The Current Status of Heterocyclic Combinatorial Libraries, CHEM. REV., vol. 97, pgs. 449-472, 1997.
	DE	NICHOLS, et al., Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists, THE EMBO JOURNAL, vol. 17, no. 3, pgs. 765-773, 1998.
	DF	NOLTE, et al., Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ, NATURE, vol. 395, pgs. 134-143, September 10, 1998. Missing pages 139, 140, and 141.
	DG	NORRIS, et al., Identification of the Sequences within the Human Complement 3 Promoter Required for Estrogen Responsiveness Provides Insight into the Mechanism of Tamoxifen Mixed Agonist Activity, MOL. ENDO., vol. 10, no. 12, pgs. 1605-1616, 1996.
	DH	NORRIS, et al., Identification of a Third Autonomous Activation Domain within the Human Estrogen Receptor, MOLECULAR ENDOCRINOLOGY, vol. 11, no. 6, pgs. 747-754, 1997.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO: PAIGE=1D	SERIAL NO: 09/429,331
LIST DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT: PAIGE, et al.	
	FILING DATE: October 28, 1999	GROUP: 1627

OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)

	DI	OLIPHANT, et al., Cloning of random-sequence oligodeoxynucleotides, GENE, vol. 44, pgs. 177-183, 1986.
	DJ	OSBORNE, et al., Nucleic Acid Selection and the Challenge of Combinatorial Chemistry, vol. 97, pgs. 349-370, 1997.
	DK	PAECH, et al., Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites, SCIENCE, vol. 277, pgs. 1508-1510, September 5, 1997.
	DL	PATTERSON, et al., Neighborhood Behavior: A Useful Concept for Validation of "Molecular Diversity" Descriptors, J. MED. CHEM., vol. 39, pgs. 3049-3059, 1996.
	DM	PELLETIER, et al., Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments, PROC. NATL. ACAD. SCI. USA, vol. 95, pgs. 12141-12146, October 1998.
	DN	PENNISI, Elizabeth, Differing Roles Found for Estrogen's Two Receptors, SCIENCE, vol. 277, pg. 1439, September 5, 1997.
	DO	RASENICK, et al., Synthetic Peptides as Probes for G Protein Function, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 34, pgs. 21519-21525, 1994.
	DP	REHRAUER, et al., Interaction of *Escherichia coli* RecA Protein with LexA Repressor, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 39, pgs. 23865-23873, 1996.
	DQ	REMY, et al., Erythropoietin Receptor Activation by a Ligand-Induced Conformation Change, SCIENCE, vol. 283, pgs. 990-993, February 12, 1999.
	DR	RINGEL, et al., Clinical Implications of Genetic Defects in G Proteins, MEDICINE, vol. 75, no. 4, pgs. 171-184, 1996.
	DS	ROSSI, et al., Monitoring protein-protein interactions in intact eukaryotic cells by β-galactosidase complementation, PROC. NATL. ACAD. SCI. USA, vol. 94, pgs. 8405-8410, August 1997.
	DT	SHIAU, et al., The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen, CELL, vol. 95, pgs. 927-937, December 23, 1998.
	DU	SIMON, et al., Peptoids: A modular approach to drug discovery, PROC. NATL. ACAD. SCI. USA, vol. 89, pgs. 9367-9371, October 1992.
	DV	SMITH, et al., Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface, SCIENCE, vol. 223, pgs. 1315-1317, June 14, 1985.
	DW	SZÖLLŐSI, et al., Application of Fluorescence Resonance Energy Transfer in the Clinical Laboratory: Routine and Research, CYTOMETRY (COMMUNICATIONS IN CLINICAL CYTOMETRY), vol. 34, pgs. 159-179, 1998.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO: PAIGE=1D	SERIAL NO: 09/429,331
LIST DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT: PAIGE, et al.	
	FILING DATE: October 28, 1999	GROUP: 1627

OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)

	DX	TREMBLAY, et al., Ligand-independent Activation of the Estrogen Receptors α and β by Mutations of a Conserved Tyrosine Can Be Abolished by Antiestrogens, CANCER RESEARCH, vol. 58, pgs. 877-881, March 1, 1998.
	DY	TZUKERMAN, et al., Human Estrogen Receptor Transactivational Capacity is Determined by both Cellular and Promoter Context and Mediated by Two Functionally Distinct Intramolecular Regions, MOLECULAR ENDOCRINOLOGY, vol. 8, no. 1, pgs. 21-30, 1994.
	DZ	VASAVADA, et al., A contingent replication assay for the detection of protein-protein interactions in animal cells, PROC. NATL. ACAD. SCI. USA, vol. 88, pgs. 10686-10690, December 1991.
	EA	WEINSTEIN, et al., An Information-Intensive Approach to the Molecular Pharmacology of Cancer, SCIENCE, vol. 275, pgs. 343-349, January 17, 1997.
	EB	WILLSON, et al., Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone, ENDOCRINOLOGY, vol. 138, no. 9, pgs. 3901-3911, 1997.
	EC	WILLSON, et al., 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats, J. MED. CHEM., vol. 37, pgs. 1550-1552, 1994.
	ED	WOODBURY, et al., Methods of screening combinatorial libraries using immobilized or restrained receptors, JOURNAL OF CHROMATOGRAPHY, vol. 725, pgs. 113-137, 1999.
	EE	WYLIE, et al., GAIP, a $G\alpha_{i-3}$-binding protein, is associated with Golgi-derived vesicles and protein trafficking, AM. J. PHYSIOL., vol. 276, pgs. C497-C506, 1999.
	EF	XU, et al., Cells that register logical relationships among proteins, PROC. NATL. ACAD. SCI. USA, vol. 94, pgs. 12473-12478, November 1997.
	EG	YANG, et al., Protein-peptide interactions analyzed with the yeast two-hybrid system, NUCLEIC ACIDS RESEARCH, vol. 23, no. 7, pgs. 1152-1156, 1995.
	EH	HALL, et al., Development of Peptide Antagonists That Target Estrogen Receptor β-Coactivator Interactions, MOLECULAR ENDOCRINOLOGY, vol. 14(12), pgs. 2010-2023, 2000.
	EI	MCDONNELL, et al., Circumventing Tamoxifen Resistance in Breast Cancer Using Mechanistically Novel Antiestrogens, Department of Pharmacology and Cancer Biology, Novalon Pharmaceutical Corp., Glaxo-Wellcome Research and Development, 2 pgs.
	EJ	NORMAN, et al., Genetic Selection of Peptide Inhibitors of Biological Pathways, SCIENCE, Vol. 285, pgs. 591-594, July 23, 1999.
	EK	PAIGE, et al., Development of a Method for Identifying Agonists and Antagonists of Orphan Receptors, ABSTRACT 147, in Conference Proceedings booklet, p. 63, for A KEYSTONE SYMPOSIUM, NUCLEAR RECEPTOR GENE FAMILY, (Incline Village, Nevada, March 28-April 3, 1998), also including pp. 1-2, and 8-10 of booklet; and copy of poster presentation (12 pp.).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.